Role of imaging in multiple myeloma

Francis I. Baffour; Katrina N. Glazebrook; Shaji K. Kumar; Stephen M. Broski

doi:10.1002/ajh.25846

Role of imaging in multiple myeloma

Francis I. Baffour, Katrina N. Glazebrook, Shaji K. Kumar, Stephen M. Broski

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

With rapid advancements in the diagnosis and treatment of multiple myeloma (MM), imaging has become instrumental in detection of intramedullary and extramedullary disease, providing prognostic information, and assessing therapeutic efficacy. Whole-body low dose computed tomography (WBLDCT) has emerged as the study of choice to detect osteolytic bone disease. Positron emission tomography/computed tomography (PET/CT) combines functional and morphologic information to identify MM disease activity and assess treatment response. Magnetic resonance imaging (MRI) has excellent soft-tissue contrast and is the modality of choice for bone marrow evaluation. This review focuses on the imaging modalities available for MM patient management, highlighting advantages, disadvantages, and applications of each.

Original language	English (US)
Pages (from-to)	966-977
Number of pages	12
Journal	American journal of hematology
Volume	95
Issue number	8
DOIs	https://doi.org/10.1002/ajh.25846
State	Published - Aug 1 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25846

Cite this

@article{435c456b864243a69fa70aa5eff2adc8,

title = "Role of imaging in multiple myeloma",

abstract = "With rapid advancements in the diagnosis and treatment of multiple myeloma (MM), imaging has become instrumental in detection of intramedullary and extramedullary disease, providing prognostic information, and assessing therapeutic efficacy. Whole-body low dose computed tomography (WBLDCT) has emerged as the study of choice to detect osteolytic bone disease. Positron emission tomography/computed tomography (PET/CT) combines functional and morphologic information to identify MM disease activity and assess treatment response. Magnetic resonance imaging (MRI) has excellent soft-tissue contrast and is the modality of choice for bone marrow evaluation. This review focuses on the imaging modalities available for MM patient management, highlighting advantages, disadvantages, and applications of each.",

author = "Baffour, {Francis I.} and Glazebrook, {Katrina N.} and Kumar, {Shaji K.} and Broski, {Stephen M.}",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, Inc.",

year = "2020",

month = aug,

day = "1",

doi = "10.1002/ajh.25846",

language = "English (US)",

volume = "95",

pages = "966--977",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "8",

}

TY - JOUR

T1 - Role of imaging in multiple myeloma

AU - Baffour, Francis I.

AU - Glazebrook, Katrina N.

AU - Kumar, Shaji K.

AU - Broski, Stephen M.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - With rapid advancements in the diagnosis and treatment of multiple myeloma (MM), imaging has become instrumental in detection of intramedullary and extramedullary disease, providing prognostic information, and assessing therapeutic efficacy. Whole-body low dose computed tomography (WBLDCT) has emerged as the study of choice to detect osteolytic bone disease. Positron emission tomography/computed tomography (PET/CT) combines functional and morphologic information to identify MM disease activity and assess treatment response. Magnetic resonance imaging (MRI) has excellent soft-tissue contrast and is the modality of choice for bone marrow evaluation. This review focuses on the imaging modalities available for MM patient management, highlighting advantages, disadvantages, and applications of each.

AB - With rapid advancements in the diagnosis and treatment of multiple myeloma (MM), imaging has become instrumental in detection of intramedullary and extramedullary disease, providing prognostic information, and assessing therapeutic efficacy. Whole-body low dose computed tomography (WBLDCT) has emerged as the study of choice to detect osteolytic bone disease. Positron emission tomography/computed tomography (PET/CT) combines functional and morphologic information to identify MM disease activity and assess treatment response. Magnetic resonance imaging (MRI) has excellent soft-tissue contrast and is the modality of choice for bone marrow evaluation. This review focuses on the imaging modalities available for MM patient management, highlighting advantages, disadvantages, and applications of each.

UR - http://www.scopus.com/inward/record.url?scp=85084835525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084835525&partnerID=8YFLogxK

U2 - 10.1002/ajh.25846

DO - 10.1002/ajh.25846

M3 - Review article

C2 - 32350883

AN - SCOPUS:85084835525

SN - 0361-8609

VL - 95

SP - 966

EP - 977

JO - American journal of hematology

JF - American journal of hematology

IS - 8

ER -

Role of imaging in multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this